MIF and in situ carcinoma: Proving a pathogenetic role of the MIF cytokine family in CIS would allow us to design novel tailored therapeutic approaches to specifically counteract MIF and DDT in this condition, or at least for some specific forms of them, initially for example for those patients that are poor responders to current early DMT treatment.